B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsDowngradesPrice Target
B of A Securities analyst Jason Gerberry downgrades Amphastar Pharma (NASDAQ:AMPH) from Neutral to Underperform and lowers the price target from $25 to $20.
B of A Securities analyst Jason Gerberry downgrades Amphastar Pharma (NASDAQ:AMPH) from Neutral to Underperform and lowers the price target from $25 to $20.